A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Dose Escalation, Multiple-Dose Escalation, and Food Effect Study of FLX475 in Healthy Male and Female Subjects
Phase of Trial: Phase I
Latest Information Update: 08 Nov 2018
At a glance
- Drugs FLX-475 (Primary)
- Indications Cancer
- Focus Adverse reactions; First in man
- Sponsors FLX Bio
- 08 Nov 2018 Results presented in the FLX Bio media release.
- 08 Nov 2018 According to an FLX Bio media release, data from this trial will be presented on November 10, 2018 at the Society for Immunotherapy of Cancer Meeting in Washington D.C.
- 21 Dec 2017 According to an FLX Bio media release, the first subject has been dosed in this trial.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History